Cypress Capital Management (Wyoming)’s Tvardi Therapeutics TVRD Stock Holding History

Cypress Capital Management (Wyoming)’s Portfolio TVRD Stock Details TVRD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q4	–	Sell	-1	Closed	-$2K	–	314
2021 Q3	$2K	Buy	+1	New	+$502	﹤0.01%	229
2021 Q2	–	Hold	0	–	–	–	295
2021 Q1	–	Sell	-14	Closed	-$8K	–	303
2020 Q4	$8K	Sell	14 -111	-89%	-$58.2K	0.01%	193
2020 Q3	$63K	Buy	125 +111	+793%	+$64.5K	0.06%	105
2020 Q2	$9K	Buy	+14	New	+$7.73K	0.01%	162
2019 Q4	–	Sell	-7	Closed	-$52K	–	205
2019 Q3	$52K	Buy	7 +5	+250%	+$4.16K	0.06%	100
2019 Q2	$35K	Sell	2 -1	-33%	-$703	0.04%	133
2019 Q1	$38K	Buy	+3	New	+$1.8K	0.05%	126
2018 Q4	–	Hold	0	–	-$5K	–	383
2018 Q3	–	Hold	0	–	–	–	306

Other funds holding TVRD

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Rockefeller Capital Management New York $56.4B AUM 24.96% 1-Year Est. Return

FCM

Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Shay Capital New York $1.2B AUM 37.4% 1-Year Est. Return

Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

CRC

Curi RMB Capital Chicago, Illinois $5.62B AUM 18.93% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Cypress Capital Management (Wyoming)'s TVRD Position: Q4 2024 in Review

Cypress Capital Management (Wyoming) sold out of Tvardi Therapeutics (TVRD) in Q4 2024, closing a stake of 139 shares — an estimated $1.54K sold.

Cypress Capital Management (Wyoming) first reported a position in TVRD in Q2 2018 and held it in 20 quarters. The position peaked at $3.08M in Q2 2020. 43 funds tracked by Wall St. Rank hold TVRD as of Q4 2024.

Cypress Capital Management (Wyoming) reported no remaining Tvardi Therapeutics position as of Q4 2024 after selling out during the quarter.
Cypress Capital Management (Wyoming) sold 139 Tvardi Therapeutics shares in Q4 2024, an estimated $1.54K.
Cypress Capital Management (Wyoming) first reported a position in Tvardi Therapeutics in Q2 2018 and held it in 20 quarters.
Cypress Capital Management (Wyoming)'s Tvardi Therapeutics position peaked at $3.08M in Q2 2020.
43 funds tracked by Wall St. Rank held Tvardi Therapeutics as of Q4 2024.

Based on Cypress Capital Management (Wyoming)'s 13F filing for Q4 2024, filed 23 Jan 2025.